Advertisement

Clinical Rheumatology

, Volume 29, Issue 4, pp 399–403 | Cite as

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

  • Mariangela Atteno
  • Rosario Peluso
  • Luisa Costa
  • Stefania Padula
  • Salvatore Iervolino
  • Francesco Caso
  • Alessandro Sanduzzi
  • Ennio Lubrano
  • Antonio Del Puente
  • Raffaele ScarpaEmail author
Original Article

Abstract

The aim of this study is to compare effectiveness and safety of Infliximab (INF), Etanercept (ETN), and Adalimumab (ADA) in patients with psoriatic arthritis (PsA) with inadequate response to a previous disease-modifying antirheumatic drug (DMARD). One hundred consecutive PsA patients with inadequate response to a previous DMARD entered this study. Clinical and laboratory assessment at baseline (T0) and 12 (T12) months were performed and included physical examination, vital signs, global Psoriasis Area and Severity Index (PASI; extension of psoriasis), tender joints count (TJC), swollen joint count, health assessment questionnaire (HAQ; questionnaire for measuring disability), and monitoring of adverse events (AEs). After enrolment, all patients were randomly given INF 5 mg/Kg every 6–8 weeks, ETN 50 mg weekly, or ADA 40 mg every other week. Baseline therapy with DMARD remained unchanged. Effectiveness was defined as percentage of ACR20 responders and as clinical remission and/or minimal disease activity at 12 months treatment. INF, ETN, and ADA all effectively controlled signs and symptoms of PsA. All variables tested showed at T12 for each treatment a significant variation from the baseline value. In particular, patients on INF and ADA showed the greatest improvement in terms of PASI, while patients on ETN showed the greatest improvement on TJC and HAQ. ACR response rates were 72% of patients on ETN, 70% of those on ADA, and 75% of those patients on INF. Occurrence of AEs was reported in 15% of the cases. Only two AEs in patients on INF were considered drug related, pneumonitis and thrombocytopenia, respectively. All tumor necrosis factor-α blockers significantly controlled signs and symptoms of PsA. An increased knowledge of the different profiles of these agents may help in optimizing their use.

Keywords

Minimal disease activity Psoriatic arthritis Remission TNF-α blockers 

Notes

Disclosures

None.

References

  1. 1.
    Wright V, Moll JMH (1971) Psoriatic arthritis. Bull Rheum Dis 21:627–632PubMedGoogle Scholar
  2. 2.
    Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12):1460–1468CrossRefGoogle Scholar
  3. 3.
    Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33(7):1422–1430PubMedGoogle Scholar
  4. 4.
    Salvarani C, Olivieri I, Pipitone N, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M, Italian Society for Rheumatology (2006) Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 24(1):70–78PubMedGoogle Scholar
  5. 5.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis. Arthritis Rheum 54:2665–2673CrossRefPubMedGoogle Scholar
  6. 6.
    de Vlam K, Lories RJ (2008) Remission in psoriatic arthritis. Curr Rheumatol Rep 10(4):297–302CrossRefPubMedGoogle Scholar
  7. 7.
    Sokoll KB, Helliwell PS (2001) Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28(8):1842–1846PubMedGoogle Scholar
  8. 8.
    Buskila D, Langevitz P, Gladman DD, Urowitz S, Smythe HA (1992) Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 19(7):1115–1119PubMedGoogle Scholar
  9. 9.
    Gladman D, Mease PJ (2006) Towards International Guidelines for the management of Psoriatic Arthritis. J Rheumatol 33(7):1228–1230PubMedGoogle Scholar
  10. 10.
    Scarpa R, Peluso R, Atteno M, Manguso F, Spanò A, Iervolino S et al (2008) The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomized 6-month trial with methotrexate. Clin Rheumatol 27(7):823–826CrossRefPubMedGoogle Scholar
  11. 11.
    Gladman D (2008) Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheum 4(10):510–511CrossRefGoogle Scholar
  12. 12.
    De Vlam K (2006) Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 45(3):321–324CrossRefGoogle Scholar
  13. 13.
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272CrossRefPubMedGoogle Scholar
  14. 14.
    Van der Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929, published online 2008 Aug 12CrossRefPubMedGoogle Scholar
  15. 15.
    Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701CrossRefPubMedGoogle Scholar
  16. 16.
    Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53Google Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Mariangela Atteno
    • 1
  • Rosario Peluso
    • 1
  • Luisa Costa
    • 1
  • Stefania Padula
    • 1
  • Salvatore Iervolino
    • 1
  • Francesco Caso
    • 1
  • Alessandro Sanduzzi
    • 2
  • Ennio Lubrano
    • 3
  • Antonio Del Puente
    • 1
  • Raffaele Scarpa
    • 1
    Email author
  1. 1.Department of Clinical and Experimental Medicine, Rheumatology Research Unit, Early Psoriatic Arthritis ClinicUniversity Federico IINaplesItaly
  2. 2.Department of Clinical and Experimental Medicine, Division of Respiratory DiseasesUniversity Federico IINaplesItaly
  3. 3.Fondazione Maugeri, IRCCSInstitute for Rehabilitative MedicineTelese TermeItaly

Personalised recommendations